Case-based course delves into latest treatment approaches
Emerging diagnostics, therapies and procedures are improving the outlook for patients with colorectal cancer, yet this rapidly changing treatment landscape can be confusing. Similarly, healthcare providers are confounded by high rates of colorectal cancer in patients under the age of 50. The 9th annual colorectal oncology course, held at Marco Island, Florida on October 6-7, 2023, will feature panel discussions and Q&As with noted specialists across surgery, radiation oncology and genomics managing this complex disease.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
“This essential update on the latest treatment changes in colorectal cancer will provide a multidisciplinary approach that’s crucial for disease management,” says Alok Khorana, MD, Director, Gastrointestinal Malignancies Program at Cleveland Clinic Cancer Center. “The program also brings focus to diagnosing and treating young-onset colorectal cancer.”
This two-day program is ideal for oncologists, surgeons, radiation oncologists, nurses and other healthcare professionals with an interest in treating patients with colorectal cancer. “For clinicians who may be too busy to attend large conferences, this national symposium a convenient way to get up to speed on everything that’s new in treating this disease.”
In this in-depth symposium, learners will gain a detailed look at a wide range of topics, including:
The live event is designated for a maximum of 8.25 American Medical Association PRA Category 1 Credits™ and 8.25 American Nurses Credentialing Center contact hours.
Advertisement
Advertisement
Timing and type of side effects differ greatly from chemotherapy
Dedicated multidisciplinary teams support 84 ultra-rare cancers
Sessions explore treatment advances and multidisciplinary care
New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues
Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations
Early communication between oncologists and ophthalmologist warranted
Long-term relationship building and engagement key to gaining community trust
FDA-approved therapy offers promise for patients with castrate-resistant prostate cancer